Value of Immediate Post-operative Intravesical Epirubicin in Intermediate&High Risk Non Muscle Invasive Bladder Cancer

• Status: Completed
• Trial end date: 2017-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The aim of the study is to test the value of immediate post-operative intravesical instillation of epirubicin in patients with intermediate and high risk non muscle invasive bladder cancer (NMIBC).

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Mansoura University
• Treatments: Doxorubicin; Epirubicin

Criteria

Inclusion Criteria:

• Ability to give informed consent.

• Patients with primary or recurrent papillary Non muscle invasive bladder cancer (NMIBC).

• Complete transurethral resection of bladder tumor(TURBT).

• Normal cardiac, hematological, and renal functions.

• Patients with intermediate and high risk NMIBC confirmed by histopathology.

Exclusion Criteria:

• Inability to give informed consent.

• Patients with history of previous radiotherapy or systemic chemotherapy.

• Patients suffering from immuno-deficiency or other malignancies.

• Patients with history of hypersensitivity reaction to epirubicin.

• Examination under anesthesia (EUA) reveals palpable bladder mass.

• Patients with primary, single, less than 1cm papillary bladder tumor (high likelihood of being low risk).

• Suspicion of perforation of the bladder during TURBT.

• Patients who develop hematuria in the recovery room necessitating continuous bladder wash or endoscopic haemostasis.

• Patients with proven low risk NMIBC on histopathology.